Ephedrine Sintetica: Uses, Dosage & Side Effects

What Is Ephedrine Sintetica and What Is It Used For?

Ephedrine Sintetica contains the active substance ephedrine hydrochloride, a non-catecholamine sympathomimetic amine that has been used in clinical medicine for over a century. Originally derived from plants of the Ephedra genus (particularly Ephedra sinica), which have been used in traditional Chinese medicine for thousands of years, modern pharmaceutical preparations use synthetically manufactured ephedrine (hence the brand name "Sintetica," denoting its synthetic origin). The drug is presented as a clear, colorless solution for injection at a concentration of 10 mg/mL, intended for intravenous administration by trained healthcare professionals.

The primary clinical indication for Ephedrine Sintetica is the treatment and prevention of hypotension that occurs during neuraxial anesthesia (spinal and epidural anesthesia) and general anesthesia. Hypotension is one of the most common adverse effects of neuraxial anesthesia, occurring in up to 80% of patients undergoing spinal anesthesia, depending on the definition used and the patient population studied. During spinal anesthesia, the local anesthetic agent blocks sympathetic nerve fibers in the spinal cord, leading to vasodilation in the lower body, reduced venous return to the heart, and consequent drops in blood pressure. If left untreated, significant hypotension can lead to organ hypoperfusion, nausea, vomiting, and in severe cases, cardiovascular collapse.

Ephedrine works through a unique dual mechanism of action that distinguishes it from many other vasopressors. Its direct action involves binding to and activating both alpha-adrenergic receptors (causing vasoconstriction) and beta-adrenergic receptors (increasing heart rate and myocardial contractility). Its indirect action involves stimulating the release of norepinephrine (noradrenaline) from storage vesicles in sympathetic nerve terminals, which then acts on adrenergic receptors throughout the cardiovascular system. This combined direct and indirect mechanism produces a comprehensive hemodynamic response that includes increased systolic and diastolic blood pressure, increased heart rate (positive chronotropy), increased myocardial contractility (positive inotropy), and increased cardiac output.

The mixed alpha- and beta-adrenergic activity of ephedrine offers certain clinical advantages compared to pure alpha-agonists such as phenylephrine. While alpha-agonists primarily increase blood pressure through vasoconstriction (which can reflexively decrease heart rate), ephedrine's beta-adrenergic effects help maintain or increase heart rate and cardiac output. This makes ephedrine particularly useful in situations where bradycardia (slow heart rate) accompanies hypotension, as it can address both problems simultaneously.

Ephedrine has been included on the World Health Organization (WHO) Model List of Essential Medicines, underscoring its importance in global healthcare. It remains a widely available and affordable vasopressor that is stocked in virtually every operating room and anesthetic department worldwide. While newer vasopressors and more targeted hemodynamic management strategies have emerged, ephedrine continues to play a valuable role in the anesthesiologist's pharmacological toolkit, particularly in resource-limited settings and in specific clinical scenarios where its unique pharmacological profile offers advantages over alternative agents.

What Should You Know Before Taking Ephedrine Sintetica?

Contraindications

Ephedrine Sintetica must not be used in certain clinical situations where its sympathomimetic effects could pose serious risks. The following are absolute contraindications to the use of intravenous ephedrine:

• Hypersensitivity: Known allergy to ephedrine hydrochloride or any of the excipients in the formulation. Although true allergic reactions to ephedrine are extremely rare, any patient with a documented history of hypersensitivity should not receive the drug.
• Concurrent MAO inhibitor therapy: Patients who are currently taking monoamine oxidase inhibitors (such as phenelzine, tranylcypromine, isocarboxazid, or selegiline at higher doses) or who have taken these medications within the past 14 days must not receive ephedrine. MAO inhibitors prevent the breakdown of norepinephrine and other catecholamines, and when combined with ephedrine's ability to release stored norepinephrine, the result can be a potentially fatal hypertensive crisis with severe elevation of blood pressure, risk of intracranial hemorrhage, and cardiovascular collapse.
• Severe hypertension: Patients with uncontrolled severe hypertension should not receive ephedrine, as its vasopressor effects would further elevate blood pressure to dangerous levels.

Warnings and Precautions

Ephedrine should be used with caution in the following conditions, and the anesthesiologist will carefully weigh the benefits against the risks:

• Cardiovascular disease: Patients with ischemic heart disease, heart failure, cardiac arrhythmias, or cor pulmonale require careful monitoring when receiving ephedrine. The increased heart rate and myocardial oxygen demand caused by ephedrine may worsen myocardial ischemia or precipitate arrhythmias in vulnerable patients.
• Hypertension: Even in patients with controlled hypertension, ephedrine should be used cautiously and at lower doses, as these patients may exhibit an exaggerated blood pressure response.
• Hyperthyroidism: Patients with thyrotoxicosis have increased sensitivity to sympathomimetic amines, and ephedrine may exacerbate tachycardia, tremor, and other symptoms of thyroid excess.
• Diabetes mellitus: Ephedrine can increase blood glucose levels through stimulation of hepatic glycogenolysis and inhibition of insulin secretion. Blood glucose monitoring may be necessary.
• Angle-closure glaucoma: Ephedrine causes mydriasis (pupil dilation), which can precipitate an acute attack of angle-closure glaucoma in susceptible individuals.
• Prostatic hyperplasia: The alpha-adrenergic effects of ephedrine can worsen urinary retention in patients with benign prostatic hyperplasia.
• Phaeochromocytoma: Ephedrine may trigger a hypertensive crisis in patients with catecholamine-secreting tumors and should be avoided.

Additionally, clinicians should be aware of the phenomenon of tachyphylaxis, a progressive decrease in the blood pressure response to repeated doses of ephedrine. This occurs because the indirect component of ephedrine's action depends on the release of stored norepinephrine from sympathetic nerve terminals. With repeated dosing, these norepinephrine stores become depleted, and subsequent doses produce a diminished hemodynamic response. When tachyphylaxis develops, the clinician should consider switching to a direct-acting vasopressor such as phenylephrine or norepinephrine.

Pregnancy and Breastfeeding

Ephedrine crosses the placenta and has historically been one of the most commonly used vasopressors for treating hypotension during spinal anesthesia for cesarean delivery. For decades, it was considered the vasopressor of choice in obstetric anesthesia because of concerns that pure alpha-agonists such as phenylephrine might reduce uterine blood flow. However, a substantial body of evidence accumulated since the early 2000s has demonstrated that phenylephrine is actually associated with better fetal acid-base outcomes (lower incidence of fetal acidosis) compared with ephedrine.

The mechanism for this difference relates to ephedrine's ability to cross the placenta more readily than phenylephrine. Once in the fetal circulation, ephedrine stimulates fetal metabolism and oxygen consumption, leading to relative fetal hypoxia and lactic acidosis, as reflected in lower umbilical artery pH values. A landmark meta-analysis published in Anesthesiology by Lee et al. (2002) and subsequent systematic reviews by Ngan Kee (2010) and others have consistently confirmed this finding.

Current guidelines from the European Society of Anaesthesiology and Intensive Care (ESAIC), the American Society of Anesthesiologists (ASA), and the National Institute for Health and Care Excellence (NICE) now recommend phenylephrine as the first-line vasopressor for cesarean section spinal anesthesia. However, ephedrine remains a valuable second-line agent, particularly in situations where maternal bradycardia accompanies hypotension, as its beta-adrenergic effects help maintain heart rate. In many clinical settings, a combination approach using phenylephrine as the primary vasopressor with ephedrine reserved for episodes of bradycardia is considered optimal.

Ephedrine is excreted in breast milk, but given that it is a single-dose intraoperative medication with a relatively short duration of action, the amount transferred to the infant through breastfeeding is expected to be negligible. Breastfeeding can generally be resumed after the effects of the anesthetic have worn off, as advised by your anesthesiologist.

Elderly Patients

Elderly patients are more susceptible to the cardiovascular effects of sympathomimetic drugs and may experience exaggerated blood pressure responses to ephedrine. Lower initial doses and more cautious titration are recommended in older patients. The reduced cardiac reserve, increased arterial stiffness, and higher prevalence of cardiovascular comorbidities in elderly populations necessitate careful hemodynamic monitoring during ephedrine administration.

Children

Ephedrine may be used in pediatric patients for the treatment of anesthesia-induced hypotension, though dosing must be adjusted for body weight. The typical pediatric dose is 0.1–0.3 mg/kg administered as an intravenous bolus, repeated as necessary. Pediatric patients should be monitored closely for tachycardia and excessive blood pressure elevation. As with adults, the medication is administered only by qualified healthcare professionals in monitored clinical settings.

How Does Ephedrine Sintetica Interact with Other Drugs?

Drug interactions with ephedrine are of particular clinical importance in the perioperative setting, where patients are frequently receiving multiple medications simultaneously. The anesthesiologist must be aware of all concurrent medications to safely manage vasopressor therapy. The following table summarizes the major drug interactions with ephedrine:

Major Interactions

The interaction between ephedrine and monoamine oxidase inhibitors (MAOIs) is the most clinically significant and potentially lethal. MAOIs prevent the enzymatic degradation of norepinephrine, dopamine, and serotonin in sympathetic nerve terminals. When ephedrine is administered to a patient taking an MAOI, the combination of increased norepinephrine release (caused by ephedrine) and impaired norepinephrine breakdown (caused by the MAOI) can lead to a massive and sudden elevation in catecholamine levels. This can produce a hypertensive emergency with blood pressures exceeding 250/150 mmHg, potentially leading to intracranial hemorrhage, aortic dissection, myocardial infarction, or death. This interaction can persist for up to two weeks after discontinuation of the MAOI.

The interaction with volatile anesthetic agents is particularly relevant in the operating room setting. Halogenated agents, especially halothane (less commonly used today), sensitize the myocardium to the arrhythmogenic effects of catecholamines. When ephedrine is administered during halothane anesthesia, the risk of ventricular tachycardia, ventricular fibrillation, and other serious arrhythmias is increased. Modern volatile agents such as sevoflurane and desflurane are less arrhythmogenic than halothane but still carry some degree of myocardial sensitization. Anesthesiologists should use the minimum effective dose of ephedrine and monitor cardiac rhythm closely.

The concurrent use of ephedrine with oxytocin deserves particular mention in the obstetric setting. Oxytocin is routinely administered after delivery of the baby to promote uterine contraction and prevent postpartum hemorrhage. Both ephedrine and oxytocin have vasopressor properties, and their combined use can lead to severe and sustained hypertension. When both agents are required during cesarean delivery, they should be administered cautiously with close blood pressure monitoring.

Minor Interactions

Several other medications can modestly enhance or diminish the effects of ephedrine without reaching the level of clinical danger seen with the major interactions described above. Corticosteroids can increase vascular sensitivity to catecholamines, potentially enhancing the blood pressure response to ephedrine. Theophylline and other methylxanthines may have additive stimulant effects when combined with ephedrine, potentially increasing the risk of tachycardia and tremor. Antihypertensive agents of various classes may have their blood pressure-lowering effects partially counteracted by ephedrine administration, which is often the therapeutic intent during anesthesia-induced hypotension.

What Is the Correct Dosage of Ephedrine Sintetica?

Ephedrine Sintetica is always administered by qualified healthcare professionals, typically anesthesiologists, nurse anesthetists, or critical care physicians, in monitored clinical environments. Dosing is highly individualized based on the patient's hemodynamic response, the clinical context, and the underlying cause of hypotension. The following guidelines represent standard dosing recommendations based on current evidence and clinical practice guidelines.

Adults

For the typical adult patient undergoing spinal anesthesia, the standard approach is to administer 3–6 mg of ephedrine (0.3–0.6 mL of the 10 mg/mL solution) as a slow intravenous bolus over approximately 30–60 seconds. The blood pressure response is assessed over the following 2–3 minutes. If the blood pressure remains below the target (typically defined as maintaining systolic blood pressure above 90 mmHg or within 20% of the patient's baseline), additional boluses of 3–6 mg may be administered at 3–4 minute intervals.

The maximum recommended dose of approximately 30 mg reflects both efficacy and safety considerations. Beyond this cumulative dose, the risk of excessive tachycardia, hypertension, and arrhythmias increases, while tachyphylaxis often limits further hemodynamic benefit. If blood pressure remains inadequate after 30 mg of ephedrine, the clinician should consider alternative vasopressors (such as phenylephrine or norepinephrine infusion), volume resuscitation, or investigation of other causes of hypotension.

Children

In pediatric patients, ephedrine is dosed based on body weight at 0.1–0.3 mg/kg per intravenous bolus. For a 20 kg child, this would correspond to 2–6 mg per dose. As with adults, the dose is titrated to blood pressure response, and cumulative dosing should be minimized to reduce the risk of adverse effects. Pediatric patients generally require proportionally similar or slightly lower doses on a mg/kg basis compared to adults.

Elderly

Elderly patients often exhibit increased sensitivity to sympathomimetic agents due to age-related changes in autonomic nervous system function, reduced baroreceptor sensitivity, and increased arterial stiffness. Lower initial doses (1.5–3 mg) with slower titration are recommended. The blood pressure response should be carefully monitored, and dose intervals may need to be extended to allow full assessment of each dose's effect before administering additional medication.

Missed Dose

The concept of a missed dose does not apply to Ephedrine Sintetica, as it is an acute-use medication administered in a hospital setting under direct medical supervision. It is not a regularly scheduled medication that patients take at home. Each dose is given in response to a specific hemodynamic need (e.g., blood pressure falling below a target threshold), and dosing decisions are made in real time by the attending clinician based on continuous blood pressure monitoring.

Overdose

Overdose with ephedrine can produce severe hypertension, tachycardia, cardiac arrhythmias (including ventricular tachycardia and ventricular fibrillation), pulmonary edema, myocardial ischemia, intracranial hemorrhage, seizures, and in extreme cases, death. The management of ephedrine overdose is primarily supportive and symptom-directed:

• Severe hypertension: Can be treated with short-acting vasodilators such as intravenous phentolamine (an alpha-adrenergic blocker), sodium nitroprusside, or glyceryl trinitrate.
• Tachycardia and arrhythmias: May respond to intravenous beta-blockers such as esmolol (a short-acting beta-1 selective blocker), although beta-blockers should be used cautiously as they can unmask alpha-adrenergic vasoconstriction and worsen hypertension.
• Seizures: Should be treated with intravenous benzodiazepines (e.g., diazepam or midazolam).
• Cardiovascular monitoring: Continuous ECG and arterial blood pressure monitoring should be maintained until the patient is hemodynamically stable.

The relatively short half-life of ephedrine (3–6 hours) means that the effects of overdose, while potentially severe, are self-limiting. There is no specific antidote for ephedrine overdose; treatment is supportive with careful hemodynamic management.

What Are the Side Effects of Ephedrine Sintetica?

Like all sympathomimetic medications, Ephedrine Sintetica can cause side effects related to its stimulation of adrenergic receptors throughout the body. The frequency and severity of side effects are dose-dependent and are influenced by the patient's underlying health status, concurrent medications, and the clinical context in which the drug is used. Because ephedrine is administered in a monitored hospital setting, side effects are typically identified and managed promptly by the attending healthcare team.

The side effects listed below are categorized by frequency of occurrence based on clinical experience, pharmacovigilance data, and the medical literature. In the perioperative setting, many of these effects overlap with the physiological changes caused by anesthesia itself, making precise attribution to ephedrine sometimes difficult.

The cardiovascular side effects of ephedrine are the most clinically significant and require the closest monitoring. Tachycardia is an expected pharmacological effect resulting from beta-1 adrenergic stimulation and is usually mild (heart rate increase of 10–20 beats per minute). However, in patients with pre-existing cardiac disease, even modest increases in heart rate can increase myocardial oxygen demand and potentially trigger ischemia or arrhythmias.

Hypertension following ephedrine administration is dose-dependent and usually transient. In most patients, the blood pressure returns to baseline within 10–15 minutes as the drug's effects dissipate. However, excessive blood pressure elevation (overshoot hypertension) can occur, particularly in patients who are volume-depleted, those receiving concurrent vasoconstrictive medications, or when doses are administered too rapidly or in excessive amounts.

Nausea and vomiting are common during the perioperative period and can be exacerbated by ephedrine's effects on the gastrointestinal tract. Ephedrine stimulates both central emetic pathways and peripheral gastrointestinal motility through its sympathomimetic action. The incidence of nausea may be higher when ephedrine is used to treat hypotension during cesarean delivery under spinal anesthesia, where the combination of uterine manipulation, hypotension, and sympathomimetic effects creates a particularly emetogenic environment.

If you experience any side effects during or after receiving ephedrine, inform your healthcare team immediately. In the monitored hospital setting, most side effects can be quickly identified and managed with appropriate supportive care.

How Should You Store Ephedrine Sintetica?

Ephedrine Sintetica is a hospital-use medication, and its storage is managed by the hospital pharmacy department according to strict pharmaceutical guidelines. However, understanding proper storage conditions is important for ensuring the medication maintains its potency and safety throughout its shelf life.

The solution for injection should be stored at a temperature below 25°C (77°F). It should not be refrigerated or frozen, as extreme cold can affect the stability of the solution or cause crystal formation. The ampoules should be kept in the original outer carton to protect from light, as ephedrine can undergo photodegradation when exposed to prolonged direct light, potentially forming degradation products that reduce potency.

Before use, the solution should be visually inspected for particulate matter, discoloration, or container damage. Only clear, colorless solutions in undamaged ampoules should be used. Any solution that appears discolored, cloudy, or contains visible particles should be discarded. Once an ampoule is opened, the solution should be used immediately. Any unused portion remaining in the ampoule after a single use should be discarded and not saved for later use, as the product does not contain preservatives and opened ampoules are at risk of microbial contamination.

The expiration date printed on the ampoule and outer carton must be respected. Do not use Ephedrine Sintetica after the expiration date (indicated as EXP on the packaging). The expiration date refers to the last day of that month. Expired medications should be returned to the hospital pharmacy for proper disposal according to local pharmaceutical waste regulations.

What Does Ephedrine Sintetica Contain?

Understanding the complete composition of Ephedrine Sintetica is important for identifying potential allergies or intolerances to any of the ingredients, and for ensuring compatibility when mixing with other intravenous solutions.

Active Ingredient

The active substance is ephedrine hydrochloride at a concentration of 10 mg per mL. Ephedrine hydrochloride is the hydrochloride salt form of ephedrine, a phenylpropanolamine derivative with the chemical formula C₁₀H₁₅NO·HCl and a molecular weight of 201.69 g/mol. The hydrochloride salt form enhances the water solubility of ephedrine, making it suitable for injectable formulations. Ephedrine exists as two stereoisomers, and pharmaceutical-grade ephedrine hydrochloride used in Ephedrine Sintetica refers to the (1R,2S)-ephedrine (also known as l-ephedrine or (-)-ephedrine), which is the naturally occurring and more pharmacologically potent isomer.

Excipients (Inactive Ingredients)

• Sodium chloride: Added to make the solution isotonic (matching the osmolarity of blood plasma), which minimizes pain and irritation at the injection site and prevents hemolysis of red blood cells.
• Water for injections: Highly purified, sterile water used as the solvent for the active ingredient and excipients. It meets stringent pharmacopoeial standards for sterility, pyrogenicity, and particulate content.
• Hydrochloric acid and/or sodium hydroxide: Used in small quantities to adjust the pH of the solution to the appropriate range (typically pH 4.5–7.0), ensuring stability of the active ingredient and compatibility with intravenous administration.

The formulation is preservative-free, which means each ampoule is intended for single use only. The absence of preservatives such as benzyl alcohol or parabens is important for patient safety, particularly in neonates and infants, where preservatives can cause adverse reactions. The solution is packaged in glass ampoules to protect against contamination and ensure long-term stability.

Each ampoule typically contains 1 mL of solution (10 mg of ephedrine hydrochloride). The ampoules are packaged in cartons, with the number of ampoules per carton varying by market. The glass used for the ampoules is Type I hydrolytic glass, which provides the highest level of chemical resistance and ensures that no components leach from the glass into the solution during storage.